SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2024 Biotech Charity Contest

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: technetium who wrote (68)5/4/2024 6:04:47 PM
From: technetium1 Recommendation

Recommended By
BulbaMan

  Read Replies (1) of 97
 
Wow.This is certainly different than two weeks ago. As the lady (approximately) said: “Buckle up Folks. It's going to be a bumpy (market).”

Yes it was a good week for the NASDAQ Composite (+5.7%). But we laugh at such paltry gains when compared to the land of biotech, Ha! Ha! (Nasdaq biotech index +7.7%; S&P biotechs gain +8.9%)!!! Wait. Sorry. Somehow I was overcome by the exuberance of animal sprits. I’m calmer now.

But it WAS a good week. Those index gains pushed both biotech composites back into the black YTD. But it’s the particulars for the contest we’re interested in here.

At the top of this week’s performers is CU6.AX, listed (as the “.AX” denotes) on the Australian market. Most of the year it’s been noodling around without drawing much attention to itself. This week, however, since Tuesday morning each day was a signifier gain, with Friday being icing on the cake, to get a a total gain for the week of +59%. There is nothing on the wire, but they are in a promising phase III though the last news was a press release of two months ago.

Second place, is a familiar face: JSPR, +52%, enough to move it up to second place in the YTD standings (+210%). VKTX is still in first YTD (+310%).

In third, VERU returned +50%, and had four articles on the news wire last week. Three of these were from the company: that they will have their quarterly financials announced next week, that they will attend a “summit” meeting, and that they are now enrolling patients for a Phase IIb trial. The third, release Tuesday morning, might be the source of the buy sentiment. (The fourth was a Zacks technical analyst touting the appearance of a “Golden Cross’ as a reason to consider VERU. Private opinion: technical analysis is functionally equivalent to reading tea leaves.)

TMDX (+44%) strongly exceeded expatiations at the release 1st quarter financials, triggering a tsunami of analyst reports. ARDX (+37%) also released Q1 financials AND the announcement of the release of additional performance data at an upcoming meeting.

Looking at the losers, CRDF shows that exceeding expectations in Q1 results on Thursday afternoon was not a guaranteed win. Instead it lost big Friday, for a weeklong loss of -37%. So in this case they clearly disappointed the Market's expectations. But they are still a pretty big win, YTD (+138%), dropping two places in those standings to fourth.

The second worst for the week, KZIA, -22%, with much of the loss after announcing a “Successful Stage I” trial. Not successful enough I guess. BRNS (-8.7%) announced hiring a new Chief Medical office and canceling some elements of the CEO’s compensation. (How often does that happen?) ITRM (-6.1%) announced resubmitting a New Drug Application, with possible approval Q4.

And for the portfolios, this week saw an uptick of $9.7lk in their average value. In fact EVERY portfolio made a profit this week, enough to move five more portfolios into the black YTD.

First place went to BULBAMAN, +$19k, +$11.7k from their faith in CU6.AX. This allowed them to surge past BLADERUNNER by +$9.6k, into first place,YTD (+$76k).

The second best return for the week was DEW_DILIGENCE, $17k, moving them past TECHNETIUM into the fifth place YTD (+$22k).

Report Time Ranges











From

To

















Recent

4/26/24

5/3/24

















YTD

12/31/2023









Index Portfolios’ Performance









Symbol

Recent P/L

Recent %

YTD P/L

















^IXIC

$5,824.38

5.7%

$7,627.39

















^NBI

$7,179.11

7.7%

$172.93

















^SPSIBI

$8,246.87

8.9%

$970.29









Share Performance

Recent Performance

YTD Performance



Top Five



Bottom Five



Top Five



Bottom 5

Symbol

P/L / Initial Price

Symbol

P/L / Initial Price

Symbol

YTD P/L / Initial Price

Symbol

YTD P/L/ Initial Price

CU6.AX

58.7%

CRDF

-37.2%

VKTX

313.6%

AMLX

-86.2%

JSPR

52.2%

KZIA

-22.3%

JSPR

210.8%

CNSP

-82.6%

VERU

50.0%

BRNS

-8.7%

PYXS

143.3%

PACB

-81.3%

TMDX

44.3%

ITRM

-6.1%

CRDF

137.8%

NERV

-61.5%

ARDX

37.1%

SCLP.L

-3.8%

VERU

126.4%

RVNC

-55.1%

Average and Median Portfolio Performance



Recent P/L







YTD P/L







Avg.

Median







Avg

Median







$9,664.37

$8,832.56

ARTHUR RADLEY



$12,512.14

$3,079.50

KATHLEEN

Top Seven Portfolio Performances

Top Recent Performers

Top YTD Performers

Contestant (Prev. Rank)

Recent P/L

P/L vs. ^SPSIBI

YTD P/L (Rank)

Contestant (Prev. Rank)

YTD P/L

vs. Top Portfolio

P/L vs. ^SPSIBI

Rec. P/L (Rank)

1 - BULBAMAN (1)

$18,938.21

$10,691.34

$75,592.86 (1)

1 - BULBAMAN (2)

$75,592.86

——

$74,622.57

$18,938.21 (1)

2 - DEW_DILIGENCE (7)

$16,937.32

$8,690.45

$21,667.94 (5)

2 - BLADERUNNER (1)

$65,966.37

$9,626.49

$64,996.09

$9,195.47 (7)

3 - RAJU_BIJLEE (5)

$14,151.84

$5,904.97

$33,238.16 (3)

3 - RAJU_BIJLEE (3)

$33,238.16

$42,354.71

$32,267.87

$14,151.84 (3)

4 - KATHLEEN (10)

$12,088.78

$3,841.91

$3,079.50 (9)

4 - ERIKOTTO (4)

$29,708.45

$45,884.41

$28,738.16

$11,722.17 (5)

5 - ERIKOTTO (6)

$11,722.17

$3,475.31

$29,708.45 (4)

5 - DEW_DILIGENCE (6)

$21,667.94

$53,924.93

$20,697.65

$16,937.32 (2)

6 - DART LANZER (3)

$9,240.16

$993.29

$1,046.62 (11)

6 - TECHNETIUM (5)

$18,735.27

$56,857.59

$17,764.98

$5,848.87 (16)

7 - BLADERUNNER (17)

$9,195.47

$948.60

$65,966.37 (2)

7 - TRACE I11 (7)

$10,933.08

$64,659.78

$9,962.79

$6,883.05 (13)

8 - JACK HARTMANN (8)

$8,856.55

$609.68

$6,403.99 (8)

8 - JACK HARTMANN (8)

$6,403.99

$69,188.87

$5,433.71

$8,856.55 (8)

Top Portfolios’ Contents

Second Place Recent Performance Portfolio (DEW_DILIGENCE)

Top YTD Performance Portfolio (BULBAMAN)

Symbol (Rank)

Initial Allocation

Value/Total | ROI

YTD Stock P/L

Recent Stock P/L

% Current Price Change for $1,000 P/L

Symbol (Rank)

Initial Allocation

Value/Total | ROI

YTD Stock P/L

Recent Stock P/L

% Current Price Change for $1,000 P/L

AVIR

6.25%

6.3% | 22.0%

$1,382.81

$483.48

13.1%

CU6.AX

20.00%

21.2% | 86.5%

$17,298.05

$11,749.00

2.7%

BNTX

6.25%

4.7% | -9.3%

-$586.66

$338.07

17.6%

CYTH

10.00%

5.4% | -5.0%

-$503.14

$1,572.33

10.5%

ENTA

25.00%

31.5% | 52.6%

$13,191.70

$7,068.06

2.6%

LRMR

10.00%

9.7% | 70.7%

$7,065.93

$2,912.09

5.9%

FRLN

0.00%

0.0% | 2.0%

$408.16

$0.00

----

PMN

10.00%

9.7% | 70.4%

$7,043.48

-$173.91

5.9%

MRNA

6.25%

6.7% | 29.4%

$1,841.90

$1,105.92

12.3%

SNGX

10.00%

3.0% | -46.8%

-$4,677.63

-$138.16

18.8%

RVNC

25.00%

10.4% | -49.6%

-$12,457.01

$1,760.70

7.9%

TCON

10.00%

3.0% | -46.9%

-$4,688.75

$142.78

18.8%

VIR

25.00%

21.2% | 2.9%

$735.86

$5,371.50

3.9%

TLX.AX

15.00%

12.5% | 46.8%

$7,015.70

$730.09

4.5%

VKTX

6.25%

19.3% | 273.3%

$17,151.18

$809.60

4.3%

VKTX

15.00%

35.3% | 313.6%

$47,039.23

$2,144.01

1.6%

















































Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext